Quest Diagnostics Upgraded by Barclays, Price Target Increased to $210
ByAinvest
Friday, Jan 30, 2026 12:42 pm ET1min read
DGX--
Quest Diagnostics (DGX) has been upgraded by Barclays, increasing its price target to $210 from $195. The upgrade reflects the company's 4% organic growth potential from 2024 to 2025 and anticipated earnings outperformance in 2026. Analysts are confident in Quest's growth trajectory and valuation opportunities.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet